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Take Home Message – Eppin is a low molecular weight protein which is expressed in the 
human lung during inflammation.  
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Abstract 
Eppin is a serine protease inhibitor expressed in male reproductive tissues. In this study we 
have demonstrated novel sites of eppin expression in myeloid and epithelial cell lines with 
further confirmation in primary myeloid cell types. Using immunohistochemistry and 
Western blotting, eppin was detected in the lungs of patients with Acute Respiratory 
Distress Syndrome and Cystic Fibrosis lung disease. Expression of eppin in monocytic cells 
was unaffected by stimulation with TLR agonists, cytokine stimulation and hormone 
receptor agonist stimulation. However, upregulated expression and secretion of eppin was 
observed following treatment of monocytes with epidermal growth factor (EGF). Incubation 
of recombinant eppin with monocytic cells resulted in significant inhibition of 
lipopolysaccharide (LPS)-induced chemokine production. Furthermore, eppin inhibited LPS-
induced NF-κB activation by a mechanism which involved accumulation of phosphorylated 
IκBα. In an in vivo model of lung inflammation induced by LPS, eppin administration resulted 
in decreased recruitment of neutrophils to the lung with a concomitant reduction in the 
levels of the neutrophil chemokine MIP-2. Overall, these results suggest a role for eppin 
outside of the reproductive tract and that eppin may have a role in the innate immune 
response in the lung. 
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Introduction 
Human epididymal protease inhibitor (eppin, SPINLW1, WFDC7) is a cysteine-rich protein 
comprised of both a Kunitz-type and a WAP (whey acidic protein) four-disulfide core (WFDC) 
protease inhibitor consensus motif [1, 2]. In the epididymis, eppin is secreted by epithelial 
cells and is a key component in the eppin protein complex which mediates the capacitation 
of spermatozoa [3]. In this role, eppin acts both as a serine protease inhibitor, inhibiting the 
action of prostate specific antigen [4], while protecting the spermatozoa from potential 
damage by bacteria [3, 5]. The majority of work on eppin to date has therefore focused on 
the development of eppin as target for a male contraceptive based on inhibition of the 
eppin protein complex via specific antibodies [6]. 
 
Although eppin is a serine protease inhibitor, the arrangement of cysteine residues differs 
from that of SLPI and elafin, the two most prominent members of the WFDC family [7]. 
Similar to SLPI  and elafin, recombinant eppin inhibited elastase activity, but unlike SLPI, 
eppin had no effect on trypsin or chymotrypsin activities [8–11]. Split domain studies 
demonstrated that the serine antiprotease activity resides solely in the Kunitz domain of 
eppin, while the WFDC domain retains no antiprotease activity [9]. Like SLPI [12], findings 
suggest that eppin also possesses antibacterial activity against Escherichia coli and that this 
effect is mediated via membrane permeabilisation [5]. In contrast to its antiprotease 
activity, the antibacterial activity of eppin against E. coli appears to be mediated by both the 
WFDC and Kunitz domains, with maximal killing achieved by the full-length protein [9].  
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On the basis of their multiple functions, WFDC proteins are considered to play key roles in 
innate immunity at mucosal surfaces. In contrast to eppin, elafin and SLPI are constitutively 
expressed by a variety of cell types, including respiratory and intestinal epithelia as well as 
key cell types involved in the innate immune response such as mast cells, neutrophils, and 
macrophages [13–19]. Furthermore, SLPI and elafin expression is altered in response to a 
number of factors including pro-inflammatory cytokines, bacterial products, proteases and 
androgens [16, 20–22]. The anti-inflammatory activity of SLPI and elafin in vitro and in vivo is 
well documented and reviewed elsewhere [7, 23, 24]. Previous work has shown that SLPI is 
capable of inhibiting lipopolysaccharide (LPS)-induced responses [20, 25–27]. In addition, 
elafin inhibited LPS activation of monocytic cells by inhibiting NF-κB activation via a process 
partly involving accumulation of polyubiquitinated IκBα [28]. Little is known about the 
function of eppin outside of the epididymis. In this study, we expand current knowledge on 
the localisation and regulation of eppin expression, and explore its potential role as a 
multifunctional host defence protein.   
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Results  
Eppin is expressed in myeloid and airway epithelial cells  
Given that SLPI and elafin transcripts are found in a variety of cell types, we first 
investigated whether eppin had a similar pattern of expression. As expected, eppin 
expression was detected in testes and lung tissue, albeit to a lesser extent in the lung tissue 
(Figure 1A). Eppin expression was also detected in myeloid cell lines, such as THP-1 and 
U937 monocytic cells, monocyte-derived macrophages, and neutrophils differentiated from 
PLB-985 cells (Figure 1A). Furthermore, eppin was expressed in both human peripheral 
blood mononuclear cells (PBMCs) (Figure 1B) and polymorphonuclear leucocytes (PMNs) 
(Figure 1A). Expression of eppin was also detected in epithelial cell lines of the respiratory 
tract including human type-II alveolar cells (A549), as well as tracheal and bronchial 
epithelial cell lines (Figure 1B). Eppin expression was highest in testes expression and, 
expression of eppin in the other tissues/cells (relative to eppin at 100%) was: THP-1 
monocyte (80%), THP-1 macrophage (75%), U937 monocyte (65%), U937 macrophage 
(55%), PLB-985 cells (57%), PMNs (80%), A549s (39%), lung (47%), PBMCs (24%), HTEs (17%), 
CFTEs (17%), HBEs (24%) and CFBEs (22%) as determined by densitometry.  Sequencing of 
PCR products confirmed the identity of human eppin.  
 
Detection of eppin in human lung tissue, bronchoalveolar lavage fluid (BALF) and sputum 
Human lungs were perfused with LPS as outlined in the Methods section. Tissue samples 
from non-LPS perfused lobes, LPS-perfused lobes and from cystic fibrosis (CF) patients were 
used for immunohistochemistry. Some eppin staining was present in non-LPS perfused lung 
tissue (Figure 2A) and was particularly evident in the LPS-perfused (Figure 2B) and CF 
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patient (Figure 2C) lung tissues. In agreement with the eppin expression data outlined in 
Figure 1, positive staining was prominent in epithelial and immune cells using two different 
eppin antibodies, confirming the presence of eppin in the in vivo lung. In addition, eppin was 
shown to be present in BALF from patients with Acute Respiratory Distress Syndrome 
(ARDS) and in sputum from patients with CF but was not present in BALF from healthy 
volunteers (Figure 3). Eppin was detected as the same high molecular weight complex in 
ARDS BALF and CF sputum which has been shown previously in semen where eppin is 
complexed to other proteins including clusterin and lactoferrin3. There appears to be low 
microgram amounts of eppin in CF sputum and ARDS BALF as determined by densitometry 
of the CF sputum and ARDS BALF blots. Other lower molecular bands were detectable in CF 
sputum which may represent proteolytic breakdown products of the eppin complex.  
 
Eppin expression and secretion are upregulated by EGF 
In order to investigate factors that may affect eppin expression, THP-1 cells were stimulated 
with a range of inflammatory agonists and effects on eppin expression were assessed by RT-
PCR. A number of TLR agonists such as LPS (TLR4), Pam3CysSK4 (TLR2) and polyinosinic-
polycytidylic acid (TLR3) had no effect on eppin expression (data not shown). Hormone 
receptor agonists such as estradiol and progesterone are known inducers of SLPI expression 
[21, 22]. However, estradiol or progesterone did not modulate eppin expression (data not 
shown). Growth factors such as epidermal growth factor (EGF) and transforming growth 
factor-β (TGF-β) have also been shown to regulate SLPI expression [29, 30]. To investigate a 
possible role for growth factors in the modulation of eppin expression, THP-1 monocytic 
cells were stimulated with EGF, TGF-β and fibroblast growth factor (FGF) at a range of 
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concentrations. TGF-β and FGF treatment of monocytes had no effect on eppin expression 
(data not shown). However, eppin expression was increased after treatment with EGF 
(Figure 4 A and B). In agreement with this result, analysis of cell supernatants by Western 
blotting revealed the presence of increased levels of eppin in EGF-treated cell supernatants 
(Figure 4C). The identity of eppin was confirmed by following digestion of protein in SDS-
PAG pieces from EGF-treated cell supernatant followed by 1D nLC-MS-MS (reverse phase 
chromatography) to identify the protein present in the SDS-PAG samples. The two main 
peptides obtained from this analysis were ANCLNTCK and DRQCQDNKK both of which demonstrate 
100% overlap with human eppin.  
 
Effect of recombinant eppin on bacterial growth 
To investigate a potential role for eppin as a host defence protein in the lung, we expressed 
and purified recombinant human eppin. The ability of eppin to permeabilise clinically 
relevant Gram negative and Gram positive bacteria as a method of bacterial killing was 
compared to LL-37, a well-known antimicrobial peptide. Eppin permeabilised P. aeruginosa 
(Figure 5A) and Staphylococcus aureus (Figure 5B) bacterial strains and was comparable, if 
not better than, the permeabilisation observed with LL-37 particularly in the case of P. 
aeruginosa. Eppin also inhibited the growth of P. aeruginosa and S. aureus when assessed 
by radial diffusion assay, once again, with significant effect on P. aeruginosa growth (Figure 
5C). 
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Effect of recombinant eppin on LPS-induced cytokine production 
Previous work has shown that the related WFDC proteins, SLPI and elafin, can modulate LPS 
signalling in monocytic cells [26–28]. Pre-incubation of THP-1 monocytic cells with eppin for 
1 h prior to LPS stimulation significantly inhibited both the expression (Figure 6A) and 
production of IL-8 (Figure 6B). In addition, eppin pre-incubation inhibited LPS-induced 
production of IL-8 from THP-1 monocyte-derived macrophages (Figure 6C) and MIP-2 from 
murine bone marrow-derived macrophages (BMDMs) (Figure 6D). We also observed no 
significant effect of eppin on THP-1 cell viability (Figure 6E). 
 
Effects of eppin on NF-κB activation 
To investigate further the effect of eppin on the LPS signalling pathway, we evaluated the 
impact of eppin on LPS-induced activation of NF-κB. Eppin significantly inhibited LPS-
induced p65:DNA binding activity in THP-1 nuclear extracts (Figure 7A), thereby suggesting 
that the ability of eppin to inhibit LPS-induced cytokine expression may be mediated via its 
effects on the NF-κB signalling pathway. SLPI has previously been shown to inhibit LPS-
induced NF-κB activity by competing with p65 for binding to consensus sites in the promoter 
regions of target genes such as IL-8 [27]. However, in contrast to SLPI, eppin was unable to 
bind NF-κB consensus oligonucleotides (Figure 7B). Eppin’s effect on LPS signalling upstream 
of NF-κB was evaluated by Western blotting. LPS-induced degradation of IκBα was observed 
in samples over time regardless of whether eppin was present or not (Figure 7C). However, 
increased phosphorylation of IκBα was observed in the eppin-treated cells compared to cells 
treated with LPS alone (Figure 7C).  
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Eppin inhibits LPS-induced lung neutrophil recruitment in vivo 
To determine if eppin might alter LPS effects in vivo, the effects of eppin in an in vivo model 
of LPS-induced acute lung inflammation were investigated. Mice receiving eppin exhibited a 
significant reduction in pulmonary total cell counts following intratracheal LPS 
administration (Figure 8A) with a significant decrease in neutrophil counts (Figure 8B). This 
decrease in neutrophil infiltration was associated with a reduction in levels of the neutrophil 
chemoattractant MIP-2 in BAL fluid from mice that received eppin and LPS compared to LPS 
alone (Figure 8C). These data confirm the in vitro findings for MIP-2 shown in Figure 5D and 
suggest that eppin may play an immunomodulatory role in the airways by reducing LPS-
induced MIP-2 production from host cells with a subsequent reduction in neutrophil 
recruitment. 
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Discussion 
The majority of work on eppin to date has focused on its role within the male reproductive 
tract. In this study, we have identified novel sites of eppin expression in both myeloid and 
epithelial cell types. Furthermore, eppin expression was confirmed in primary mononuclear 
cells and neutrophils. We have also demonstrated the presence of eppin in tissue and 
airways (BALF and sputum) from patients with ARDS and CF, as well as from human ex vivo 
lung tissue perfused with LPS. Given the similar sites of expression we have demonstrated 
between eppin and other WFDC genes, we examined whether the expression of eppin in 
monocytic cells was modulated by factors known to regulate the expression of SLPI and/or 
elafin. However, we found that eppin expression was not induced by various TLR agonists, 
hormone receptor agonists and cytokine stimuli used in this study.  
 
These findings are similar to those reported for HE4 (WFDC2), another WFDC family 
member. HE4 was originally thought to be limited to the reproductive tract however, the 
expression profile of HE4 has since expanded to include the trachea, lung and nasal 
epithelium as well as major and minor salivary glands [13, 31]. HE4 expression was not 
affected by pro-inflammatory agonists such as IL-1β and TNF-α [14]. Although SLPI 
expression is induced by hormone receptor agonists such as estradiol and progesterone, 
elafin expression is unaffected [21, 22]. In addition, growth factors have been shown to 
regulate SLPI expression in vitro and in vivo [29, 30, 32]. In this study, eppin expression in 
monocytic cells was unaffected by estradiol and progesterone treatment (data not shown), 
however, both eppin expression and secretion were up-regulated by EGF treatment. We 
have also provided evidence of eppin protein in the lungs of patients with Cystic Fibrosis and 
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ARDS by immunohistochemistry and Western blot indicating that eppin is increased during 
inflammation with little eppin present in healthy lung. It should be highlighted that further 
confirmation of eppin presence in diseased lung could be provided by the availability of 
more specific monoclonal antibodies to eppin as there is a paucity of eppin antibodies 
available to carry out definitive in vivo studies. However, our immunohistochemistry and 
Western blot data does correlate to the eppin expression detected in lung epithelial and 
inflammatory cells as shown in Figure 1. Eppin was not detected as a monomeric species in 
CF and ARDS airway secretions but was present as a high molecular weight complex or 
oligomeric species in these biological fluids which has been shown previously in semen 
where eppin is complexed to other proteins including clusterin and lactoferrin3.  
 
For the purposes of investigating a potential host defence role for eppin, we expressed and 
purified recombinant eppin [9]. Our subsequent analyses focused on exploring the 
antibacterial and immunomodulatory potential of eppin. Recombinant eppin has previously 
been shown to inhibit growth of E. coli [5, 9]. In this study, we expand these observations by 
demonstrating an antibacterial effect of eppin against P. aeruginosa and S.aureus, two 
clinically relevant pulmonary pathogens. Although there are limitations associated with the 
radial diffusion assay, the bacterial membrane permeabilisation assay provides more 
definitive anti-bacterial activity data and the combined results of both assays serve to 
confirm that eppin has a greater effect on P. aeruginosa than S.aureus. In order to 
investigate the immunomodulatory effects of eppin, our studies focussed on the effects of 
eppin on LPS signalling and downstream responses in human monocytic cells and 
macrophages.  Pre-treatment of THP-1 monocytic cells, THP-1 monocyte-derived 
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macrophages and murine bone marrow derived macrophages with eppin prior to LPS 
stimulation, significantly decreased production of chemokines such as IL-8 and MIP-2. The 
anti-inflammatory effect of eppin was also demonstrated in an in vivo model of LPS-induced 
acute lung inflammation. Treatment of mice with recombinant human eppin resulted in a 
significant reduction in pulmonary neutrophilia and a concomitant reduction in BAL levels of 
the neutrophil chemoattractant MIP-2. 
 
Investigation of a potential mechanism to explain these findings demonstrated that eppin 
reduced NF-κB activity in THP-1 monocytic cells in response to LPS stimulation. In contrast 
to SLPI [27], the anti-inflammatory effects of eppin were not dependent on binding of eppin 
to NF-κB DNA binding sites. However, similar to SLPI and elafin, we observed increased 
levels of phosphorylated IκBα in cells pre-treated with eppin. It is not clear why incubation 
of cells with eppin results in increased phosphorylated IκBα. Evaluation of proteasome 
activity has previously shown that the chymotrypsin, trypsin nor caspase-like activities of 
the proteasome are affected by SLPI or elafin [26, 28]. Therefore, it is possible that eppin 
affects the ubiquitin-proteasome pathway at other site(s) leading to increased IκBα 
phosphorylation, decreased NF-κB activity and decreased expression of NF-κB target genes. 
Moreover, we have demonstrated the presence of eppin in human tissue and airway 
secretions and have shown an immunomodulatory role for eppin in vivo. As previously 
discussed, SLPI and elafin play several important roles in the innate immune response. The 
expression of eppin in myeloid and epithelial cell types, coupled with its documented 
biological activity, suggest that eppin may play a protective role in the innate immune 
response similar to SLPI and elafin. The importance of this potential role remains to be fully 
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explored; however, eppin may represent another important multifaceted member of the 
WFDC family. 
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Methods 
Full details are available in the online supplement. 
Cell culture  
Unless otherwise indicated, cell culture reagents were obtained from Life Technologies Ltd. 
(Paisley, UK). Human acute monocytic leukemia cells (THP-1), myelomonocytic cells (U937) 
and type-II alveolar epithelial cells (A549) were purchased from the American Type Culture 
Collection (ATCC, Manassas, USA). Human diploid myeloid leukaemia cells (PLB-985) were 
obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, 
Braunschweig, Germany). The human bronchial epithelial cell line 16HBE14o- (HBE), the CF 
bronchial epithelial cell line CFBE41o- homozygous for the F508del mutation (CFBE), the 
human tracheal epithelial cell line 9HTEo- (HTE), and the CF tracheal epithelial cell line 
CFTE29o- homozygous for the F508del mutation (CFTE) were obtained as a gift from Prof. 
Dieter Gruenert (California Pacific Medical Centre Research Institute, San Francisco, CA) [33, 
34]  
 
Recombinant protein production 
Recombinant eppin was produced as described previously [9].  
 
RNA extraction and RT-PCR 
RNA from human lung, testes tissue, primary peripheral blood mononuclear (PBMC) and 
polymorphonuclear leucocytes (PMN) cells were purchased from BioChain (Hayward, 
California, USA).  
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Analysis of secreted eppin 
THP-1 monocytic cells were incubated in serum free media for 8 h in the absence or 
presence of EGF (5 ng/ml; Peprotech, London, UK). Supernatants were collected and protein 
precipitated using a method adapted from Wessel and Fugge [35].  
 
Human lung tissue 
Lungs harvested from potential donors that were found to be unsuitable for transplantation 
were obtained from IIAM (International Institute for Advancement of Medicine). Ethical 
approval for the use of these samples was obtained from the Queen’s University Belfast 
School of Medicine, Dentistry and Biomedical Science Research Ethics Committee. The lungs 
were perfused ex vivo based on previously described methods [36, 37]. Experimentation 
ceased 4 hr after LPS instillation, upon which tissue samples for histology were taken from 
LPS-perfused lobes [36]. Lung tissue sections from CF patients were obtained from the 
University of Newcastle. Ethical approval for the use of these tissue samples was obtained 
from Newcastle and North Tyneside Ethics Committee (reference number 11/NE/0291).   
 
Immunostaining of human tissue for eppin  
Immunostaining for eppin detection was performed similar to previous methods [36].  
 
Effect of recombinant eppin in a murine model of LPS-induced lung inflammation 
C57Bl/6 mice (10 – 12 weeks of age) were used in all experiments and were purchased from 
Charles Rivers Laboratories and also bred in-house.  
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Statistical analysis 
All data were analysed using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA). 
Means were compared by unpaired t-test, Mann Whitney test, one-way analysis of variance 
(ANOVA), Kruskal-Wallis test, or one-sample t-test compared with 100 for densitometry 
data as appropriate. P < 0.05 was accepted to indicate statistical significance. Data represent 
mean ± SEM of n = 3 unless otherwise stated.  
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Figure Legends 
Figure 1. Basal expression profile of eppin in cell lines and primary cells.  
Eppin and GAPDH expression were detected in (A) THP-1 and U937 monocytic (mono) and 
monocyte-derived macrophage (mac), PLB-985 differentiated neutrophils (PLB), primary 
human neutrophils (PMN), human type II alveolar (A549) cells, testes and lung tissue, (B) 
human peripheral blood mononuclear cells (PBMC), human tracheal (HTE) and cystic fibrosis 
tracheal (CFTE), human bronchial (HBE) and cystic fibrosis bronchial epithelial (CFBE) cell 
lines by RT-PCR (35 cycles) as outlined in the Methods. Levels of eppin expression relative to 
GAPDH expression are shown between panels.  
 
Figure 2. Detection of eppin in human lung tissue.  
Tissue samples from (A) ex vivo non-LPS (B) LPS-perfused lungs and (C) cystic fibrosis lungs 
were formalin-fixed and paraffin-embedded for immunohistochemistry. Tissue sections 
were stained with 2 anti-human eppin antibodies from (i) Santa Cruz (ii) Abbexa and 
representative images (n = 2) were taken at X 20 objective lens magnification, scale bar = 50 
µm. Further zoomed in images (to the right of the main panels) were also taken to highlight 
cellular staining of eppin. Areas of eppin staining are indicated by white arrows.  
 
 
Figure 3. Detection of eppin in airway secretions 
ARDS patient BALF samples, CF sputum and healthy control BALF samples were 
electrophoresed and blotted for eppin (Abbexa). Recombinant eppin (rEppin) was run in 
each blot and migrated as monomeric, dimeric and trimeric bands. Molecular weight 
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markers are indicated to the left of each blot and the position of eppin complex indicated 
with arrows. 
 
Figure 4. Eppin is up-regulated by EGF stimulation.  
(A) THP-1 monocytic cells were incubated with media alone or with EGF (5 ng/ml) for 8 h 
and eppin expression detected by RT-PCR (35 cycles) as outlined in the Methods. (B) 
Densitometry of eppin relative to GAPDH. * P < 0.05. (C) Supernatants from control and 
EGF-treated cells were concentrated by methanol chloroform precipitation and eppin was 
detected by Western blot. The identity of eppin was confirmed by 1D nLC-MS-MS (Reverse 
Phase Chromatography). The two main peptides obtained from this analysis were ANCLNTCK and 
DRQCQDNKK both of which demonstrate 100% overlap with human eppin. 
 
Figure 5. Eppin permeabilises Gram negative and Gram positive bacteria.  
(A) P. aeruginosa and (B) S. aureus were incubated for 2 h with 5 μM SYTOX® Green nucleic 
acid stain ± eppin or LL-37 as indicated. The proportion of permeabilised bacteria was 
quantified by measuring the relative fluorescence at 480 nm (excitation) and emission 
between 510 and 700 nm using a SPECTRAmax Gemini XS fluorescence microplate reader 
and results are expressed as a % of the pre-permeabilised positive control.  (C) In radial 
diffusion assays, agarose gels were prepared containing P. aeruginosa or S. aureus and 
incubated with increasing concentrations of recombinant eppin (12.5-100g/ml) or cecropin 
(100g/ml) as a positive control. 
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Figure 6. Eppin inhibits LPS-induced cytokine production in mononuclear cells. 
(A) THP-1 monocytic cells were pre-treated with recombinant human eppin (5 μg/ml) for 1 h 
prior to 6 hr LPS stimulation. Total RNA was extracted and RT-PCR performed for IL-8 and 
GAPDH as described in the Methods section. Expression levels of IL-8 relative to GAPDH are 
shown between the panels. (B) THP-1 monocytic cells were pre-treated with recombinant 
human eppin (5 μg/ml) for 1 h prior to LPS stimulation. Cell-free supernatants were 
collected after 24 h LPS stimulation and levels of IL-8, were quantified by ELISA. (C) THP-1 
monocyte-derived macrophages and (D) murine bone marrow derived macrophages were 
pre-treated with recombinant human eppin (5 μg/ml) for 1 h prior to 24 h LPS stimulation. 
Levels of (C) human IL-8 and (D) murine MIP-2 were quantified by ELISA. *** P < 0.001 vs 
LPS. (E) THP-1 monocytic cells were incubated in cell medium or with recombinant human 
eppin (0.1, 1 and 10μg/ml) 24 h. Cell viability was assessed using Vision Blue Quick Cell 
Viability Assay reagent. 
 
Figure 7. Eppin decreases LPS-induced NF-κB activation in THP-1 monocytic cells and 
increases levels of phosphorylated IκBα.  
(A) THP-1 monocytic cells were pre-treated with recombinant human eppin (5 μg/ml) for 1 h 
followed by stimulation with LPS for 60 min. Nuclear lysates were prepared and p65 activity 
determined using a TransAm activity ELISA. * P < 0.05, *** P < 0.001 vs LPS. (B) The binding 
of eppin to the consensus NF-κB binding site was determined by EMSA. (C) THP-1 monocytic 
cells were pre-treated with recombinant human eppin (5 μg/ml) for 1 h followed by 
stimulation with LPS for 0-120 min. Cytoplasmic lysates were immunoblotted for IκBα, 
phospho-IκBα (Ser32/36) and GAPDH. 
25 
 
 
Figure 8. Recombinant eppin decreases LPS-induced neutrophil recruitment in a mouse 
model of acute lung inflammation.  
Mice received intratracheal saline (sal) or LPS ± recombinant eppin and after 4 h mice were 
sacrificed and bronchoalveolar lavage (BAL) performed. BAL (A) Total cell counts and (B) 
neutrophil counts were quantified. (C) Levels of MIP-2 in BAL fluid were quantified by ELISA. 
n = 3 – 7/group, ** P < 0.01, *** P < 0.001 vs LPS.  
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 A
 FIGURE 1
 B
Eppin 
GAPDH 
Eppin 
GAPDH 
   PBMC    HTE    CFTE   HBE    CFBE
Mono      Mac      Mono     Mac        PLB       PMN         A549    Testes   Lung    (-) RT  (-) cDNA 
       THP-1                   U937 
 0.84      0.80       0.69      0.58      0.61      0.84          0.42      1.06       0.49                                 Eppin:GAPDH
  0.25       0.18      0.18         0.26      0.23     Eppin:GAPDH
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